Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GLP-1
Biotech
Lilly triple-G bet sees 16.8% weight loss in ph. 3 diabetes test
Eli Lilly is rounding out its pitch for retatrutide with new data looking at blood sugar reductions and weight loss in patients with Type 2 diabetes.
Fraiser Kansteiner
Mar 19, 2026 6:45am
Structure touts 16% weight loss 'highest efficacy' for oral GLP1
Mar 16, 2026 10:02am
Ascletis eyes quarterly GLP-1 dosing following phase 2 readout
Mar 10, 2026 8:20am
Zealand's Zupreme serves up to 10.7% mean weight loss
Mar 5, 2026 4:44pm
How GLP-1s help the heart relax: study
Mar 2, 2026 7:01pm
AstraZeneca's oral GLP-1 scored phase 2 wins, but no data yet
Feb 10, 2026 9:58am
